Kenvue Inc. (NYSE:KVUE) Holdings Lifted by Atria Investments Inc

Atria Investments Inc lifted its stake in Kenvue Inc. (NYSE:KVUE) by 13.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 126,678 shares of the company’s stock after acquiring an additional 15,352 shares during the period. Atria Investments Inc’s holdings in Kenvue were worth $2,705,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently made changes to their positions in KVUE. Concurrent Investment Advisors LLC lifted its stake in shares of Kenvue by 131.9% in the 3rd quarter. Concurrent Investment Advisors LLC now owns 53,517 shares of the company’s stock worth $1,238,000 after acquiring an additional 30,438 shares during the period. Graypoint LLC acquired a new stake in shares of Kenvue in the 3rd quarter worth approximately $233,000. Principal Financial Group Inc. lifted its stake in shares of Kenvue by 3.2% in the 3rd quarter. Principal Financial Group Inc. now owns 2,364,451 shares of the company’s stock worth $54,690,000 after acquiring an additional 73,542 shares during the period. CWA Asset Management Group LLC acquired a new stake in shares of Kenvue in the 3rd quarter worth approximately $307,000. Finally, Galvin Gaustad & Stein LLC acquired a new stake in shares of Kenvue in the 3rd quarter worth approximately $214,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts recently commented on KVUE shares. Citigroup cut their target price on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research note on Wednesday, January 15th. Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a “buy” rating to a “hold” rating and cut their target price for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. Canaccord Genuity Group increased their target price on shares of Kenvue from $24.00 to $29.00 and gave the company a “buy” rating in a research note on Wednesday. UBS Group cut their target price on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research note on Friday, February 7th. Finally, Piper Sandler increased their target price on shares of Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a research note on Monday, February 24th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $23.75.

Kenvue Stock Up 1.2 %

KVUE stock opened at $23.46 on Friday. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $24.46. The company’s 50 day simple moving average is $21.64 and its 200-day simple moving average is $22.33. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The firm has a market capitalization of $44.83 billion, a P/E ratio of 44.25, a P/E/G ratio of 2.62 and a beta of 1.25.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. As a group, equities research analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were paid a $0.205 dividend. The ex-dividend date was Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 3.50%. Kenvue’s dividend payout ratio is presently 154.72%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.